TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
An HHS policy posted October 28 directs the FDA not to take enforcement action against specialty pharmacies selling six wellness peptides, including BPC-157, TB-500 and KPV. The peptides have not been FDA-approved for safety and effectiveness; people familiar with the policy’s development told the Associated Press that FDA scientific staff opposed the change. The policy’s legal reach and how its safety provisions will be enforced remain unclear.
The Department of Health and Human Services has directed the FDA not to take action against specialty pharmacies selling six wellness peptides, including BPC-157, TB-500 and KPV, easing access to substances that have not been approved by the agency for safety and effectiveness. People familiar with the policy’s development told the Associated Press that FDA scientific staff opposed the change and had limited input.
The policy, posted online by HHS on Wednesday, covers injectable peptides promoted for wellness uses such as muscle building, injury recovery and energy. Under existing FDA rules, the substances would otherwise be considered illegal drugs because they have not undergone the agency’s review process for safety and effectiveness. The directive does not amount to FDA approval of the peptides.
HHS Secretary Robert F. Kennedy Jr. said in the policy document that the move “advances patient choice and freedom” while protecting Americans from peptides sold online that may be made with unscreened ingredients. An HHS spokesperson said the agency was addressing risks from the black market by offering a more controlled alternative through licensed U.S. compounders.
Six people familiar with the decision told the Associated Press, speaking anonymously about confidential deliberations, that FDA drug staffers warned the change could weaken the agency’s effort to keep unproven products off the market. Two of those people said HHS initially considered a formal regulation that would have placed the peptides on a list of substances considered safe for compounding, but shifted to a non-enforcement policy after FDA officials raised safety concerns.
FDA staff provided technical assistance on the final plan, including proposed safeguards: pharmacies are directed to use ingredients from FDA-registered factories, verify peptide purity and collect information on side effects. Former FDA official Peter Lurie said the agency may lack legal authority to enforce those pharmacy requirements.
Access Expands Without FDA Approval
The policy could make these peptides easier to obtain through specialty pharmacies, but it does not establish that they are safe or effective. That distinction matters because online promotion has associated them with a wide range of conditions, even though the substances covered by the directive have not received FDA approval for those uses.
Lurie, who leads the Center for Science in the Public Interest, warned that patients could turn away from tested treatments. He said that if people are diverted from approved drugs to peptides, there could be “more unnecessary pain and suffering.” That is his assessment of potential consequences, not a finding about outcomes under the new policy.
The decision also has commercial implications. Wellness peptides have drawn interest from telehealth companies, including Hims & Hers, which previously announced plans to offer them if the government changed its policy. Wall Street analysts estimate the market could exceed $2 billion; that figure is a forecast, not a confirmed market value.
Products Worth Considering
Blueair Blue Pure 511i Max Air Purifier for Home and Bedroom
Garmin Forerunner 55 GPS Running Smartwatch, Black
Oral-B iO Series 7 Rechargeable Electric Toothbrush with 2 Brush Heads and Charging Travel Case
As an affiliate, we earn on qualifying purchases.
How the Policy Changed Course
Peptides are short chains of amino acids, and some occur naturally in the body. FDA-approved peptide-based medicines include semaglutide and tirzepatide, used in treatments for diabetes and weight loss. Those approvals followed agency review; they do not establish the safety or effectiveness of the six wellness peptides covered by the HHS policy.
According to people familiar with the deliberations, HHS first considered asking the FDA to issue a regulation deeming the substances safe for compounding. FDA staff raised safety objections, and HHS adopted a different route: directing the agency not to enforce certain rules against pharmacies that compound them. The change is a break from longstanding FDA efforts to restrict access to unproven products marketed for medical purposes.
Compounding pharmacies make customized medications, but the practice has drawn safety scrutiny. The FDA’s role in overseeing compounding gained attention after a 2012 fungal meningitis outbreak linked to contaminated injections from a Massachusetts compounding pharmacy. The source report says compounding has since grown into a multibillion-dollar industry.
““Advances patient choice and freedom.””
— Robert F. Kennedy Jr., in the HHS policy document
Scope and Safeguards Remain Unclear
The policy directs the FDA not to act against covered pharmacies, but the source report does not specify how long the directive will remain in effect or precisely how broadly it will be applied. It is also unclear how the stated safeguards will be monitored. Lurie questioned whether the FDA has legal authority to enforce the pharmacy requirements, and the report does not describe an enforcement mechanism or identify which agency would oversee compliance.
The policy does not establish whether the six peptides are safe or effective, nor does it provide clinical evidence supporting the uses promoted by wellness sellers. The identities of the people who described internal objections remain undisclosed because they spoke about confidential deliberations. HHS’s policy does not resolve those scientific questions.
Implementation and FDA Oversight
The immediate next step is for specialty pharmacies and the FDA to respond to the directive in practice. The policy calls for compounders to check ingredient purity, source ingredients from FDA-registered factories and gather side-effect information. The source report does not give a schedule for reviewing that information or say how the safeguards will be assessed.
Further clarification from HHS or the FDA could explain the directive’s legal scope, oversight responsibilities and any process for responding to safety concerns. Until then, the confirmed change is a direction to limit enforcement against pharmacies selling the named peptides—not FDA approval of the products or a determination that they are safe and effective.
Key Questions
Which peptides are covered by the HHS policy?
The policy covers six wellness peptides. The source report names BPC-157, TB-500 and KPV; it does not list the other three in the material provided.
Has the FDA approved these peptides?
No. The peptides covered by the policy have not been approved by the FDA as safe and effective. The directive to limit enforcement is not an approval.
What safeguards does the policy describe?
It directs compounders to use ingredients from FDA-registered factories, verify peptide purity and collect information about side effects. How those requirements will be monitored or enforced remains unclear.
Why did FDA staff reportedly oppose the change?
People familiar with the deliberations told the Associated Press that FDA scientists raised safety concerns and warned the policy could undermine efforts to keep unproven products off the market. The agency’s scientific staff did provide technical assistance on the final plan, according to the report.
Source: medpagetoday.com
